Sagimet Biosciences Inc. 8-K

What Happened
Sagimet Biosciences Inc. announced on May 28, 2026 that its Compensation Committee and Board granted stock options and performance-based restricted stock units (PSUs) to three executive officers. Awards: President & CEO David Happel received 300,000 options and 300,000 PSUs; CFO Thierry Chauche received 50,000 options and 50,000 PSUs; Chief Legal & Administrative Officer Elizabeth Rozek received 100,000 options and 100,000 PSUs. The grants were made under the Company’s 2023 Stock Option and Incentive Plan.

Key Details

• Grant date: May 28, 2026.
• Total awards granted: 450,000 options and 450,000 PSUs (900,000 potential shares across the three officers).
• Option exercise price: $7.27 per share (equal to the closing stock price on the grant date).
• Vesting: Options vest in equal installments over 48 months. PSUs vest based on achievement of specified regulatory milestones — one-third vests upon the committee’s determination of milestone achievement (Achievement Determination Date), and the remaining two-thirds vest in two equal installments on the first and second anniversaries of that date.

Why It Matters
These grants align executive pay with the company’s future regulatory progress and stock performance. The exercise price set at the grant-date close ($7.27) means options have value only if the stock rises above that level; PSUs are tied to regulatory milestones so they are not guaranteed shares until those milestones are met. Investors should note potential future dilution if options are exercised and PSUs are earned and settled, and monitor regulatory developments that would trigger PSU vesting.